Noopept

The verdict

Our read at a glance.

Whether a compound with a substantial Russian-language development history but almost no indexed human trial evidence does anything measurable for cognition in healthy people.

The signal

The modern indexed literature is dominated by rodent work, including intranasal administration in a PINK1 knockout Parkinsonian rat model and studies in streptozotocin-induced diabetic rats, plus analytical characterization of the molecule itself. Its original development literature is largely Russian-language and older, which is the honest reason this memo cannot cite a strong human trial: not that the compound was disproven, but that the evidence a reader can actually check is thin.

The unknown

Whether any effect on cognition exists in healthy humans, at what dose, and whether the Russian development-era claims would replicate under modern trial standards. No indexed randomized controlled trial in healthy adults establishes an effect size.

Our read

One of the most-discussed compounds in this category with one of the least checkable evidence bases. The gap here is not that studies were done and failed; it is that the studies people cite are largely not accessible or not in humans. Absence of accessible evidence is its own finding.